BIOSENSE/CORDIS CARTO 3-D CARDIAC MAPPING TECHNOLOGY SLATED TO ENTER CLINICALS FOR ABLATION PROCEDURES; IDE APPLICATION UNDER REVIEW BY FDA
This article was originally published in The Gray Sheet
Executive Summary
Biosense and Cordis are gearing up for U.S. clinical trials of cardiac ablation procedures using the firms' Carto three-dimensional electrophysiology mapping and ablation technology.